NO843773L - Fremgangsmaate for fremstilling av en inneslutningsforbindelse av 2-nitroksymetyl-6-klorpyridin - Google Patents

Fremgangsmaate for fremstilling av en inneslutningsforbindelse av 2-nitroksymetyl-6-klorpyridin

Info

Publication number
NO843773L
NO843773L NO843773A NO843773A NO843773L NO 843773 L NO843773 L NO 843773L NO 843773 A NO843773 A NO 843773A NO 843773 A NO843773 A NO 843773A NO 843773 L NO843773 L NO 843773L
Authority
NO
Norway
Prior art keywords
nitroxymethyl
chloropyridine
cyclodextrin
occlusion
compound
Prior art date
Application number
NO843773A
Other languages
English (en)
Norwegian (no)
Inventor
Yoshio Ueda
Fumio Shimojo
Kiyoshige Yoshida
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO843773L publication Critical patent/NO843773L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
NO843773A 1983-10-11 1984-09-20 Fremgangsmaate for fremstilling av en inneslutningsforbindelse av 2-nitroksymetyl-6-klorpyridin NO843773L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58190345A JPS6081166A (ja) 1983-10-11 1983-10-11 2−ニトロオキシメチル−6−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法

Publications (1)

Publication Number Publication Date
NO843773L true NO843773L (no) 1985-04-12

Family

ID=16256648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO843773A NO843773L (no) 1983-10-11 1984-09-20 Fremgangsmaate for fremstilling av en inneslutningsforbindelse av 2-nitroksymetyl-6-klorpyridin

Country Status (18)

Country Link
US (1) US4575548A (fi)
EP (1) EP0141300A3 (fi)
JP (1) JPS6081166A (fi)
KR (1) KR850003414A (fi)
CN (1) CN85102133A (fi)
AU (1) AU576521B2 (fi)
CA (1) CA1248523A (fi)
DK (1) DK461184A (fi)
ES (1) ES8506758A1 (fi)
FI (1) FI843944L (fi)
GR (1) GR80531B (fi)
HU (1) HU194285B (fi)
IL (1) IL73076A (fi)
NO (1) NO843773L (fi)
OA (1) OA07832A (fi)
PH (1) PH20203A (fi)
PT (1) PT79320B (fi)
ZA (1) ZA847350B (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
JPS60202115A (ja) * 1984-03-27 1985-10-12 Ichiro Shibauchi エポキシ樹脂用硬化剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
EP1176792A1 (en) * 2000-07-24 2002-01-30 Alcatel Method and apparatus for providing an all digital loop with power-optimised mode
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US11812951B2 (en) 2008-06-17 2023-11-14 Apollo Endosurgery Us, Inc. Endoscopic needle assembly
CA2692211C (en) * 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
HUE026288T2 (en) 2011-03-27 2016-05-30 Cellresin Tech Llc Cyclodextrin preparations, articles and procedures
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS57142962A (en) * 1981-02-28 1982-09-03 Santen Pharmaceut Co Ltd Cyclodextrin clathrate compound of sulfur-containing compound
JPS6054304B2 (ja) * 1981-10-16 1985-11-29 株式会社バコム ジソピラミド包接化合物
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
DK311683A (da) * 1982-07-26 1984-01-27 Fujisawa Pharmaceutical Co Fremgangsmaade til fremstilling af pyridylalkylnitratforbindelser
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
DE3329517A1 (de) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
DE3337802A1 (de) * 1983-10-18 1985-04-25 Merck Patent Gmbh, 6100 Darmstadt Pharmazeutische zubereitung

Also Published As

Publication number Publication date
HU194285B (en) 1988-01-28
US4575548A (en) 1986-03-11
AU3339984A (en) 1985-04-18
GR80531B (en) 1985-01-09
ES536654A0 (es) 1985-08-01
AU576521B2 (en) 1988-09-01
JPS6245226B2 (fi) 1987-09-25
ES8506758A1 (es) 1985-08-01
HUT36832A (en) 1985-10-28
OA07832A (fr) 1986-11-20
IL73076A (en) 1988-05-31
KR850003414A (ko) 1985-06-17
CA1248523A (en) 1989-01-10
JPS6081166A (ja) 1985-05-09
PH20203A (en) 1986-10-20
FI843944L (fi) 1985-04-12
FI843944A0 (fi) 1984-10-08
PT79320A (en) 1984-11-01
DK461184A (da) 1985-04-12
PT79320B (en) 1986-09-08
CN85102133A (zh) 1987-01-17
DK461184D0 (da) 1984-09-26
EP0141300A3 (en) 1986-01-29
ZA847350B (en) 1985-10-30
IL73076A0 (en) 1984-12-31
EP0141300A2 (en) 1985-05-15

Similar Documents

Publication Publication Date Title
NO843773L (no) Fremgangsmaate for fremstilling av en inneslutningsforbindelse av 2-nitroksymetyl-6-klorpyridin
US4565807A (en) Medicinal composition containing pirprofen and cyclodextrin and a method of use
RU2126397C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ТРИГИДРАТА (2R, 3S)-3-ТРЕТ-БУТОКСИ-КАРБОНИЛАМИНО-2-ГИДРОКСИ-3- ФЕНИЛПРОПИОНАТА-4-АЦЕТОКСИ -2α- БЕНЗОИЛОКСИ -5β, 20-ЭПОКСИ -1,7β,10β- ТРИГИДРОКСИ-9-ОКСО- ТАКС-11-ЕН-13α-ИЛА
US3957853A (en) Metformine salt of acetylsalicylic acid
EP0379161B1 (de) Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate
EP0470452B1 (en) A method for the production of complexes of long chain polyunsaturated fatty acids and their derivatives, with cyclodextrins, and the resulting complexes
EP0078599B1 (en) Complex compounds based on cyclodextrins
JPH03206090A (ja) シクロデキストリンとのシリビニンの封入錯体、その製造法、該化合物を含有する、肝臓製剤療法のための医薬製剤および該医薬製剤の製造法
JPH0643429B2 (ja) 高度に結晶性のナトリウムセフオペラゾンの製法
JPH03237103A (ja) α―サイクロデキストリンの包接化合物及びα―サイクロデキストリンの分離精製法
US3110711A (en) Process of producing two escin isomers from horse chestnut extracts, and products
EP1693375A1 (en) Process for preparing clopidrogel hydrogen sulfate of form I
JP3604390B2 (ja) 疎水性化合物を溶解するためおよびエナンチオマの純度を照査するためのモノ−3,6−アンヒドロシクロデキストリンの使用およびこれらのシクロデキストリンの調製方法
CA2671921A1 (en) Inclusion complex of raloxifene hydrochloride and .beta.-cyclodextrin
JPH04106101A (ja) シクロデキストリンポリマーおよびその製造方法
JPH10195108A (ja) 架橋シクロデキストリン高分子の合成方法と、該高分子によるコレステロールの除去
KR100759159B1 (ko) 파록세틴과 사이클로덱스트린 또는 사이클로덱스트린유도체의 컴플렉스
JPS62195395A (ja) 分子量分布の狭い低分子量セルロ−ス誘導体の製法
Mielcarek Studies on inclusion complexes of felodipine with β-cyclodextrin
US4072695A (en) 3α,7α-Dihydroxy-cholanic acid derivatives
JPH0741495A (ja) 14α−ヒドロキシ−4−アンドロステン−3,6,17−トリオン水和物結晶及びその製造法
EP0007159B1 (en) A chloral derivative; method for preparing this derivative and a therapeutic composition containing this derivative
JPH05507735A (ja) 高選択性と著しい低毒性を有する植物由来抗腫瘍化学療法剤ならびにその製造法
US3887175A (en) Quinidine alginate and process of preparation thereof
JPH02255692A (ja) D―グルコーl―グリセロ―3―オクチュロースの製造方法